XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Tables)

Condensed Consolidated Financial Statement Detail (Tables)

6 Months Ended

Jun. 30, 2012

Condensed Consolidated Financial Statement Detail [Abstract]

Outstanding securities considered anti-dilutive

Potentially dilutive securities are excluded from the calculation of loss per share if their inclusion is anti-dilutive. The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2012		2011		2012		2011
Common stock options and restricted stock units		5,121		3,833		5,566		3,711
Convertible preferred stock		-		17		-		135
Warrants for common stock		16,702		1,607		11,079		1,607
Total		21,823		5,457		16,645		5,453

Accrued liabilities

Accrued liabilities consisted of the following at June 30, 2012 and December 31, 2011 (in thousands):

	June 30, 2012		December 31, 2011
Accrued payroll and other benefits	$	2,306	$	3,007
Accrued management incentive compensation		1,894		4,096
Accrued clinical trial costs		1,927		140
Accrued severance payments		403		1,207
Other		1,336		1,562
Total	$	7,866	$	10,012